Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.64 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.64 |
| ▸ | PREP | P48147 | 1/20 | 0.61 |
| ▸ | FAP | Q12884 | 1/20 | 0.61 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.61 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.61 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5374969 | 1.00 | DPP4 (1.00) | DPP4OPRM1OPRD1PREPFAP | |
| SCHEMBL5366058 | 0.90 | DPP4 (1.00) | DPP4OPRM1OPRD1 | |
| SCHEMBL5368160 | 0.90 | DPP4 (0.81) | DPP4OPRM1OPRD1 | |
| SCHEMBL5366065 | 0.90 | DPP4 (1.00) | DPP4OPRM1OPRD1 | |
| SCHEMBL5368164 | 0.90 | DPP4 (0.81) | DPP4OPRM1OPRD1 | |
| SCHEMBL5364316 | 0.87 | DPP4 (0.77) | DPP4OPRM1OPRD1 | |
| SCHEMBL5364322 | 0.87 | DPP4 (0.77) | DPP4OPRM1OPRD1 | |
| SCHEMBL5376760 | 0.86 | DPP4 (0.76) | DPP4OPRM1OPRD1PREPFAP | |
| SCHEMBL5376757 | 0.86 | DPP4 (0.76) | DPP4OPRM1OPRD1PREPFAP | |
| SCHEMBL5376746 | 0.80 | DPP4 (0.67) | DPP4OPRM1OPRD1PREPFAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7205409-B2 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2007-04-17 | — | — | US | disclosed |
| US-20050131019-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131019-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | DPP4 1/4885OPRM1 2511/4885OPRD1 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.